Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy
NCT06852963Phase 2Active, not recruiting
- Sponsor
- PYC Therapeutics
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of VP-001 in retinitis pigmentosa type 11 (RP11), sponsored by PYC Therapeutics. Started Jun 2025; status: active, not recruiting.
02
Drugs
VP-001
03
Conditions
retinitis pigmentosa type 11 (RP11)
Beyond the preview
Go deeper on NCT06852963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852963.